Anti-PD-L1-TGFb antibody (M7824) in advanced non-small cell lung cancer

Division Of Basic Sciences - Nci

Investigators

Linked publications, trials & patents

Abstract

M7824 is a bifunctional monoclonal antibody targeting programmed death ligand 1 (PD-L1) and transforming growth factor-beta. The use of this drug represents a form of combination immunotherapy. Fourteen patients with advanced NSCLC have enrolled in the biomarker cohort. This includes 8 patients who have previously received immunotherapy and 6 patients who have not received immunotherapy. Three (21%) patients experienced a partial response including 2 (33%) of 6 patients who had not received immunotherapy previously. Treatment was well tolerated and the frequency of immune-related adverse events was not higher than that observed with anti-PD-1/PD-L1 monotherapy. Analysis of tissue and blood samples demonstrate tumor necrosis and immune activation. A poster based on this study was presented at the Virtual Annual Meeting of the American Society of Clinical Oncology (ASCO) in June 2020 and a manuscript is in preparation.